Global campaign to overcome antimicrobial resistance and treat acute upper respiratory tract infections: facts about pelargonium extract EPs®7630

Mozhyna T.L.

Main
Publications
Global campaign to overcome antimicrobial resistance and treat acute upper respiratory tract infections: facts about pelargonium extract EPs®7630

December 30, 2024

208

Therapy, General practice

Mozhyna T.L.

УДК: 612.215.4

DOI: 10.32471/umj.1680-3051.166.261770

Keywords :

acute respiratory infections,

EPs®7630,

evidence base,

pelargonium

Specialities :

Therapy, General practice

Resume

Modern approaches to the etiopathogenetic therapy of acute respiratory tract infections are changing under the influence of the global campaign to prevent antibiotic resistance and the active introduction of drugs with bacteriostatic and/or bactericidal properties into routine clinical practice. EPs^®7630 may be a solitary solution in the management of adults, adolescents and children over 1 year of age with acute uncomplicated respiratory tract infections, including common cold, acute bronchitis, acute rhinosinusitis, acute tonsillopharyngitis and COVID-19. The antibacterial, antiviral, anti-inflammatory, immunomodulatory and secretomotor properties of EPs^®7630 ensure the etiopathogenetic and symptomatic activity of the drug. The use of EPs^®7630 allows to follow the modern strategy of delayed use of antibiotics in acute upper respiratory tract diseases, and in some cases — to avoid antibiotic therapy completely.

References

1. http://www.who.int/campaigns/world-amr-awareness-week.
2. Інструкція для застосування препарату Умкалор® (2024) compendium.com.ua/dec/271731/11719/.
3. Malek F.A., Funk P. (2024) Identifying in-market application of Pelargonium root extract EPs®7630 for the treatment of COVID-19: analysis of pharmacovigilance data. Front. Pharmacol., 15: 1335309. doi: 10.3389/fphar.2024.1335309
4. The South African Herbal Pharmacopoeia (2023) http://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/umckaloabo).
5. Cinatl J.Jr., Wass M.N., Michaelis M. (2024) Multiple mechanisms enable broad-spectrum activity of the Pelargonium sidoides root extract EPs®7630 against acute respiratory tract infections. Front. Pharmacol., 15: 1455870. doi: 10.3389/fphar.2024.1455870.
6. Veldman L.B.M., Belt-Van Zoen E., Baars E. (2023) Mechanistic Evidence of Andrographis paniculata (Burm. f.) Wall. ex Nees, Pelargonium sidoides DC., Echinacea Species and a Combination of Hedera helix L., Primula veris L./Primula elatior L. and Thymus vulgaris L./Thymus zygis L. in the Treatment of Acute, Uncomplicated Respiratory Tract Infections: A Systematic Literature Review and Expert Interviews. Pharmaceuticals (Basel), 16(9): 1206.
7. Reina B.D., Malheiros S.S., Vieira S.M. et al. (2024) Unlocking the therapeutic potential of Pelargonium sidoides natural extract: A scoping review. Heliyon, 10(23): e40554.
8. Fang L., Zhou L., Kulić Ž. et al. (2023) EPs® 7630 Stimulates Tissue Repair Mechanisms and Modifies Tight Junction Protein Expression in Human Airway Epithelial Cells. Int. J. Mol. Sci., 24(13): 11230. doi: 10.3390/ijms241311230.
9. Tisch M., Roháč L., Reineke T. et al. (2024) Long-term benefits of EPs® 7630 in patients with acute sinusitis: a real-world cohort study. Front. Pharmacol., 15: 1358879.
10. Kardos P., Lehmacher W., Zimmermann A. et al. (2022) Effects of Pelargonium sidoides extract EPs®7630 on acute cough and quality of life — a meta-analysis of randomized, placebo-controlled trials. Multidiscip. Respir. Med., 17: 868.
11. Büttner R., Schwermer M., Ostermann T. et al. (2023) Complementary and alternative medicine in the (symptomatic) treatment of acute tonsillitis in children: A systematic review. Complement. Ther. Med., 73: 102940.
12. Matthys H., Funk P., Zimmermann A. et al. (2023) Effects of EPs®7630 on the duration of inability to work in acute bronchitis — a meta-analysis. Multidiscip. Respir. Med., 18(1): 914. doi: 10.4081/mrm.2023.914.
13. Emanuel J., Papies J., Galander C. et al. (2023) In vitro and in vivo effects of Pelargonium sidoides DC. root extract EPs® 7630 and selected constituents against SARS-CoV-2 B.1, Delta AY.4/AY.117 and Omicron BA.2. Front. Pharmacol., 14: 1214351.
14. Papies J., Emanuel J., Heinemann N. et al. (2021) Antiviral and Immunomodulatory Effects of Pelargonium sidoides DC. Root Extract EPs® 7630 in SARS-CoV-2-Infected Human Lung Cells. Front. Pharmacol., 12: 757666.
15. Sütçü M., Kara M., Yıldız F. et al. (2024) Hand, foot, and mouth disease: could EPs® 7630 be a treatment option? A prospective randomized open-label multicenter clinical study. Front. Pediatr., 12: 1274010. doi: 10.3389/fped.2024.1274010.
16. Настанова 00129. Гострий бронхіт (2017) guidelines.moz.gov.ua/documents/3030.
17. RxTest — Аудит лікарських призначень компанії.
18. Perić A., Gaćeša D., Barać A. et al. (2020) Herbal Drug EPs®7630 versus Amoxicillin in Patients with Uncomplicated Acute Bacterial Rhinosinusitis: A Randomized, Open-Label Study. Ann. Otol. Rhinol. Laryngol., 129(10): 969–976.
19. Реімбурсація Umckaloabo (2024) http://www.umckaloabo.de.
20. Kamin W., Behre U., Helm K. et al. (2023) Safety of Pelargonium extract EPs®7630 in young children with acute bronchitis. Front. Pediatr., 11: 1107984.